FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Welch David F 		2. Issuer Name and Ticker or Trading Symbol

CytoDyn Inc. [ CYDY ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

1111 MAIN STREET, SUITE 660 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/8/2019
(Street)

VANCOUVER, WA 98660
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/8/2019     M    166666   A $0.40   1129999   I   See footnote   (1)
Common Stock   5/8/2019     M    600000   A $0.40   1729999   I   See footnote   (1)
Common Stock   5/8/2019     M    500000   A $0.40   2175280   I   See footnote   (2)
Common Stock   5/8/2019     M    384615   A $0.40   2559895   I   See footnote   (2)
Common Stock   5/8/2019     A    383333   A   (3) 2112332   I   See footnote   (1)
Common Stock   5/8/2019     A    442307   A   (3) 3002202   I   See footnote   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant (Right to Buy)   $0.75   5/8/2019     D         166666    1/10/2019   1/28/2021   Common Stock   166666     (3) 0   I   See footnote   (1)
Warrant (Right to Buy)   $0.40   5/8/2019     A      166666       1/10/2019   1/28/2021   Common Stock   166666     (3) 166666   I   See footnote   (1)
Warrant (Right to Buy)   $0.40   5/8/2019     M         166666    1/10/2019   1/28/2021   Common Stock   166666   $0.00   0   I   See footnote   (1)
Warrant (Right to Buy)   $0.75   5/8/2019     D         600000    1/10/2019   2/16/2023   Common Stock   600000     (3) 0   I   See footnote   (1)
Warrant (Right to Buy)   $0.40   5/8/2019     A      600000       1/10/2019   2/16/2023   Common Stock   600000     (3) 600000   I   See footnote   (1)
Warrant (Right to Buy)   $0.40   5/8/2019     M         600000    1/10/2019   2/16/2023   Common Stock   600000   $0.00   0   I   See footnote   (1)
Warrant (Right to Buy)   $0.75   5/8/2019     D         500000    1/10/2019   9/14/2023   Common Stock   500000     (3) 0   I   See footnote   (2)
Warrant (Right to Buy)   $0.40   5/8/2019     A      500000       1/10/2019   9/14/2023   Common Stock   500000     (3) 500000   I   See footnote   (2)
Warrant (Right to Buy)   $0.40   5/8/2019     M         500000    1/10/2019   9/14/2023   Common Stock   500000   $0.00   0   I   See footnote   (2)
Warrants (Right to Buy)   $0.75   5/8/2019     D         384615    1/10/2019   9/8/2022   Common Stock   384615     (3) 0   I   See footnote   (2)
Warrants (Right to Buy)   $0.40   5/8/2019     A      384615       1/10/2019   9/8/2022   Common Stock   384615     (3) 384615   I   See footnote   (2)
Warrants (Right to Buy)   $0.40   5/8/2019     M         384615    1/10/2019   9/8/2022   Common Stock   384615   $0.00   0   I   See footnote   (2)

Explanation of Responses:
(1)  The reported securities of CytoDyn Inc. (the "Company") are held by LRFA, LLC, a Delaware limited liability company ("LRFA"). David F. Welch, Ph.D. is the sole managing member of LRFA. Dr. Welch disclaims beneficial ownership of the securities held by LRFA, except to the extent of his pecuniary interest therein.
(2)  The reported securities of the Company are held by David Welch Tr Ua 03/02/2000 Welch Charitable Remainder Unitrust Agreement II (the "Trust"), for which Dr. Welch is a trustee.
(3)  On May 8, 2019, the Company entered into Warrant Exercise Agreements with LRFA and the Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Dr. Welch, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Welch David F
1111 MAIN STREET, SUITE 660
VANCOUVER, WA 98660 		X



Signatures
/s/ Michael D. Mulholland, as attorney-in-fact 5/10/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more CytoDyn (QB) Charts.
CytoDyn (QB) (USOTC:CYDY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more CytoDyn (QB) Charts.